The majority of patients with lung cancer present with metastatic disease. Chronic inflammation and subsequent activation of nuclear factor-jB (NF-jB) have been associated with the development of cancers. The RelA/ p65 subunit of NF-jB is typically associated with transcriptional activation. In this report we show that RelA/p65 can function as an active transcriptional repressor through enhanced methylation of the BRMS1 (breast cancer metastasis suppressor 1) metastasis suppressor gene promoter via direct recruitment of DNMT-1 (DNA (cytosine-5)-methyltransferase 1) to chromatin in response to tumor necrosis factor (TNF). TNF-mediated phosphorylation of S276 on RelA/p65 is required for RelA/p65-DNMT-1 interactions, chromatin loading of DNMT-1 and subsequent BRMS1 promoter methylation and transcriptional repression. The ability of RelA/p65 to function as an active transcriptional repressor is promoter specific, as the NF-jB-regulated gene cIAP2 (cellular inhibitor of apoptosis 2) is transcriptionally activated whereas BRMS1 is repressed under identical conditions. Small-molecule inhibition of either of the minimal interacting domains between RelA/p65-DNMT-1 and RelA/p65-BRMS1 promoter abrogates BRMS1 methylation and its transcriptional repression. The ability of RelA/p65 to directly recruit DNMT-1 to chromatin, resulting in promoter-specific methylation and transcriptional repression of tumor metastasis suppressor gene BRMS1, highlights a new mechanism through which NF-jB can regulate metastatic disease, and offers a potential target for newer-generation epigenetic oncopharmaceuticals.
Introduction
Nuclear factor-kB (NF-kB) is aberrantly activated in malignancies and its activation is essential for tumor proliferation and metastatic process (Bours et al., 1994; Helbig et al., 2003; Bobrovnikova-Marjon et al., 2004; Denlinger et al., 2004; Huber et al., 2004; Karin and Greten, 2005; Takada et al., 2005) . Typically, NF-kB is a transcriptional activator after stimulation with proinflammatory cytokines, such as tumor necrosis factor (TNF) and interleukin-1 (IL-1) (Chen et al., 1998; Mayo and Baldwin, 2000) . In unstimulated cell nuclei, RelA/p65 and/or p50 are transcriptionally repressed through interactions on chromatin with histone deacetylases 1 and 3 corepressor complexes. Following stimulation, derepression of RelA/p65 occurs through phosphorylation on serines 276 (Zhong et al., 2002; Dong et al., 2008) or 536 (Hoberg et al., 2006) that enhances its association with histone acetyltransferases (HATs), allowing RelA/p65 to activate transcription (Chen et al., 1998 (Chen et al., , 2005 .
In 2004, Campbell first described the ability of RelA/ p65 to function as an 'active repressor' under specific cytotoxic stimuli (Campbell et al., 2004) . Interestingly, TNF and IL-6, both classical stimuli for NF-kB activation, have also been correlated with enhanced methylation of promoter CpG island (CGI), resulting in transcriptional repression of tumor-suppressor genes (Hodge et al., 2005; Ushijima and Okochi-Takada, 2005; Wehbe et al., 2006) . These observations suggest that under specific conditions, NF-kB activation may be related to methylation of specific genes, although the mechanisms through which this occurs are unknown.
BRMS1 (breast cancer metastasis suppressor 1) was originally identified as a tumor metastasis suppressor, and its expression levels have been shown to be markedly reduced in various cancers (Meehan and Welch, 2003; Liu et al., 2006b) ; with the loss of the BRMS1 allele coinciding with increased numbers of metastases and decreased survival in breast cancer and lung cancer patients (Hicks et al., 2006; Zhang et al., 2006; Smith et al., 2009) . We have shown that methylation of the specific CGI (À531 to þ 608) contributes to BRMS1 transcriptional repression in non-small-cell lung cancer (NSCLC) cells and human tumors (Nagji et al., 2010) .
In this report we provide evidence that RelA/p65 functions as an active transcriptional repressor through enhanced methylation of the BRMS1 promoter via direct recruitment of DNMT-1 (DNA (cytosine-5)methyltransferase 1) to chromatin in response to TNF. Our study offers new insight into an alternative mechanism through which NF-kB can function as an active transcriptional repressor to promote tumor metastasis.
Results
TNF represses BRMS1 transcription via BRMS1 promoter methylation Chronic inflammation and the proinflammatory cytokines are increasingly appreciated as contributing significantly to cancer progression (Coussens and Werb, 2002; Greten and Karin, 2004; Pikarsky et al., 2004; Karin and Greten, 2005) . In our model system the proinflammatory cytokine TNF significantly increased the invasive potential of NSCLC H157 and H1299 cells (Figure 1a ). Similarly, small interfering RNA knockdown of endogenous BRMS1 resulted in a dramatic increase in the invasive potential of NSCLC cells (Supplementary Figure S1 ).
As we have shown that BRMS1 is downregulated in NSCLC (Liu et al., 2006b) , we next sought to determine whether TNF promotes lung cancer cell invasion through regulation of BRMS1 expression. We observed that TNF reduced both protein ( Figure 1b ) and transcription ( Figure 1c ) levels of BRMS1 in a timedependent manner in NSCLC H157 and H1299 cells, and normal bronchial epithelial cells, respectively. These data suggest that repression of BRMS1 transcription is a plausible mechanism through which inflammatory cytokines promote the metastatic potential of NSCLC.
Given that methylation of the CGI results in BRMS1 transcriptional repression (Nagji et al., 2010) , we hypothesized that TNF may be decreasing BRMS1 transcription through enhanced BRMS1 promoter methylation. As we expected, TNF increased BRMS1 methylation in a time-and dose-dependent manner in normal bronchial epithelial cells (Figure 1d and Supplementary Figure S2A ). These results establish that TNF enhances BRMS1 transcriptional repression through DNA methylation.
RelA/p65 mediates TNF-induced methylation and transcriptional repression of BRMS1 The biological functions of TNF are realized primarily by activating NF-kB, particularly its active subunit RelA/p65 . To examine the requirement of endogenous RelA/p65 for enhancing BRMS1 promoter methylation following TNF treatment, p65 WT and p65 À/À mouse embryo fibroblast cells Figure 1 TNF reduces BRMS1 expression. (a) TNF promotes lung cancer cells invasion. NSCLC cells were treated with TNF (40 ng/ml) for 48 h and the invasion capability was quantified using Boyden chamber assays. Bar graphs show average cell counts per field. Data are presented as mean±s.d. *Po0.01 and **Po0.001 compared with No add. (b) TNF reduces BRMS1 protein level. NSCLC cells were treated with TNF (40 ng/ml) at the indicated time points. The protein levels of BRMS1 were evaluated by western blots. (c) TNF inhibits BRMS1 transcription. Normal bronchial epithelial (NHBE) cells were treated with TNF (40 ng/ml), and mRNA of endogenous BRMS1 was detected by quantitative reverse transcription-PCR (RT-PCR) at the indicated time points (0, 1, 2, 4, 8 and 16 h). (d) TNF induces methylation of the BRMS1 promoter. NHBE cells were treated with TNF as described in (c) and the relative methylation status of BRMS1 was evaluated by quantitative methylation-specific PCR (MSP).
RelA/p65 mediates promoter-specific methylation Y Liu et al were exposed to the demethylating reagent 5 0 -aza-2 0deoxycytidine (5-Aza) for global hypomethylation of the entire genome. Following removal of 5-Aza, the BRMS1 promoter was remethylated in the TNF-treated p65 WT cells. In contrast, in the p65 À/À cells, the BRMS1 promoter remained hypomethylated despite treatment with TNF ( Figure 2a ). Subsequent quantitative reverse transcription-PCR studies demonstrated that methylation events observed in Figure 2a correlated with decreased BRMS1 transcription levels in the TNF-treated p65 WT mouse embryo fibroblast cells ( Figure 2b ). TNF-mediated repression of BRMS1 transcription results in an approximately sixfold increase in BRMS1 promoter methylation over basal levels. Importantly, we found that under normal condition, the basal expression of RelA/p65 has little impact on the methylation status or transcription of BRMS1 (Figures 2a and b ). This strongly suggests that this process is an inducible event and RelA/p65 is actively involved in TNF-mediated BRMS1 transcriptional repression.
To investigate the effects of RelA/p65 on BRMS1 promoter methylation in NSCLC, we exploited previously generated H157 NSCLC cells that stably express SR-IkB, a dominant-negative inhibitor of NF-kB (H157I), or a vector control (H157V) (Jones et al., 2000) . As shown in Figure 2c , cells lacking the ability to activate NF-kB (H157I) have a four-fold decrease in basal BRMS1 promoter methylation levels compared with controls (H157V). In addition, even with removal of 5-Aza, the BRMS1 promoter in the H157I cells cannot be methylated, whereas H157V cells return to near basal levels at 48 h.
In addition, we also assessed methylation levels of endogenous BRMS1 promoter in H157V and H157I cells using bisulfite sequencing PCR. As shown in Supplementary Figure S2B , bisulfite sequencing PCR measurements of basal BRMS1 promoter methylation is roughly 3-to 4-fold in the H157V cells compared with H157I cells, which correlates exactly with our methylation-specific PCR results.
Collectively, these studies confirm that RelA/p65 is required for TNF-mediated methylation and transcriptional repression of BRMS1 and provide the first evidence of the potential role of RelA/p65 as an epigenetic regulator of DNA methylation.
RelA/p65 directly binds DNA in the CpG island region of the BRMS1 promoter NF-kB regulates promoter-specific transcription through binding to active kB binding site(s) (Chen et al., 1998) . Analysis of the BRMS1 promoter reveals three putative NF-kB binding sites (arbitrarily named I, II and III) that are located in the CpG island ( Figure 3a ). To determine whether NF-kB can bind these putative kB binding sites, we performed electrophoretic mobility shift assays (EMSAs) using wild-type and mutant kB binding site as probes. All three putative wild-type kB binding sites bound NF-kB using the nuclear extracts of NSCLC H157 cells ( Figure 3b ) and normal bronchial epithelial cells (Supplementary Figure  S3A ). Subsequent treatment using an anti-RelA/p65 antibody that recognizes the N-terminal region of RelA/ p65 confirmed RelA/p65 specificity. Mutation of the last two conserved cytosine (C) to adenine (A) residues in each kB binding site completely inhibited NF-kB binding to DNA (Figure 3b and Supplementary Figure  S3A ). Moreover, EMSAs indicated that TNF increases nuclear RelA/p65 and enhances NF-kB binding to the kB binding sites I and II in the BRMS1 promoter, but not site III (Figure 3c and Supplementary Figure S3B ). In summary, like classical TNF-induced NF-kB activated genes, TNF mediates BRMS1 transcriptional repression through enhanced nuclear translocation and DNA binding of RelA/p65.
To establish which kB binding site(s) were functional relative to RelA/p65-induced BRMS1 transcriptional repression, we created either individual or combined mutations in the kB binding sites in the BRMS1 reporter gene. We used site-directed mutagenesis to maintain the conformation of the BRMS1 promoter. These assays Figure 2 RelA/p65 mediates TNF-induced BRMS1 transcriptional repression via methylation. (a) RelA/p65 mediates TNF-induced methylation. p65 WT and p65 À/À mouse embryo fibroblasts (MEFs) were treated with 5-Aza (5 mM) for 5 days followed by stimulation with TNF (20 ng/ml). The relative methylation of BRMS1 was detected by quantitative methylation-specific PCR (MSP). The data are plotted as the fold over No add group, where results from the group of No add were normalized to 1 for p65 WT MEFs. *Po0.05 compared with the same time point in p65 WT control group. (b) RelA/p65 is required for TNF-induced BRMS1 transcriptional repression. p65 WT and p65 À/À MEFs were treated with 5-Aza and TNF in the same pattern as described in (a). The mRNA of BRMS1 was analyzed by quantitative reverse transcription-PCR (RT-PCR). *Po0.05 compared with the same time point in p65 WT control group. (c) RelA/p65 mediates methylation of the BRMS1 promoter in NSCLC. H157 V/I cells were treated with 5-Aza (5 mM) as described previously. Relative methylation of BRMS1 promoter was determined by quantitative MSP at the indicated time point. *Po0.05 and **Po0.01 compared with the same time point in H157I; w Po0.05 compared with No add of H157V.
RelA/p65 mediates promoter-specific methylation Y Liu et al demonstrate that RelA/p65 failed to repress the transcriptional activity of the BRMS1 promoter that has the kB binding site II mutation, whereas mutation of the other two kB binding sites, individually or in combination (data not shown), had no effect on RelA/ p65, TNF or combined TNF/RelA/p65-induced repression ( Figure 3d ). Collectively, these results demonstrate that although all three kB binding sites in the BRMS1 promoter can bind NF-kB, site II appears to have more functional significance with respect to TNF and/or RelA/p65-mediated repression of BRMS1 transcription.
RelA/p65 is required for assembly of selective DNMTs on the BRMS1 promoter Given the requirement of DNMT-1 in the methylation process (Okano et al., 1999; Bestor, 2000) , we next examined whether RelA/p65 endogenously forms complexes with DNMT-1. As shown in Figure 4a , RelA/p65 has minimal interaction with DNMT-1 in the absence of TNF. However, there is a robust increase in the endogenous interaction of RelA/p65 and DNMT-1 following TNF treatment. Furthermore, we found that the combination of DNMT-1 and DNMT-3b resulted in the most robust repression of BRMS1 transcriptional activity following ectopic expression of RelA/p65 (Supplementary Figure S4A) .
To examine the requirement for RelA/p65 in loading of key methylation components on chromatin, chromatin immunoprecipitation (ChIP) assays indicated that removal of 5-Aza resulted in recruitment of DNMT-1 ( Figure 4b ) and DNMT-3b (Supplementary Figure S4B ) to the BRMS1 promoter in H157V, but not in the H157I cells in a time-dependent manner. The presence or absence of RelA/p65 had no effect on loading of DNMT-3a (Supplementary Figure S4B ). Review of the data in Figure 4b and Supplementary Figure S4C suggests that the re-recruitment of DNMT-3b on chromatin occurs earlier (B24 h) when compared with DNMT-1 (B36-48 h). Not surprisingly, methylated histone H3-K9 chromatin occupancy was increased on the BRMS1 promoter in the presence of RelA/p65 only. Subsequent western blot analyses confirmed that the (a) Schematic illustration of the CpG island in BRMS1 promoter. Arrow, the transcription start site; blank box, exon 1; black squares, the putative NF-kB binding sites; small bars, the primers for methylation-specific PCR (MSP). (b) NF-kB binds to the kB binding sites on the BRMS1 promoter. EMSAs performed using P 33 -labeled wild-type or mutant kB binding sites as probe incubated with NSCLC H157 nuclear extracts. (c) TNF enhances NF-kB binding to the NF-kB sites I and II. NSCLC H157 cells were treated with TNF (40 ng/ml) for 15 min. EMSAs performed as described in (b). The relative expression of RelA/p65 in nuclear (NE) and cytoplasmic (CE) extracts was evaluated by western blot. b-Actin and RNA pol II were probed as controls for cytoplasmic and nuclear protein, respectively. (d, upper) Diagram of wild-type and mutated BRMS1 promoter. Black boxes, wild type kB binding site; unfilled boxes, the mutant kB binding site. (d, lower) NSCLC H157 cells were co-transfected with indicated BRMS1 promoter reporter genes and RelA/p65 or empty vector. Post transfection (24 h), the cells were treated with or without TNF (40 ng/ml) for an additional 18 h. Luciferase activity was analyzed. The data are plotted as the fold over control, where results from control in each group were normalized to 1. *Po0.05 compared with control for each group.
observed decreases of chromatin-associated DNMT-1 and DNMT-3b in the H157I cells were not secondary to regulation by RelA/p65 (Figure 4b and Supplementary Figure S4B ).
Given that heterodimer RelA/p65/p50 is the most common form of NF-kB, small interfering RNA knockdown of p50 resulted in significant loss of chromatin-associated RelA/p65, DNMT-1 and methylation on the BRMS1 promoter ( Figure 4c ). Interestingly, reducing p50 expression did not affect RelA/p65 loading to the promoter of a known NF-kB-regulated gene, cIAP2 (cellular inhibitor of apoptosis 2) (Liu et al., 2006a) . These data suggested that RelA/p65 mediates methylation and transcriptional repression of BRMS1 through heterodimerization with p50.
To determine if TNF-induced chromatin loading of DNMTs is promoter specific, we examined the promoter regions of BRMS1, cIAP2 as well as GAPDH (glyceraldehyde 3-phosphate dehydrogenase). Although chromatin occupancy of RelA/p65 increased with TNF concentration ( Figure 4d ) and time (Supplementary Figure S4C ) across both the BRMS1 and cIAP2 promoters, no DNMTs were recruited to the cIAP2 promoter, presumably secondary to an absence of a CpG island in the cIAP2 promoter (Figure 4d and Supplementary Figure S4C ).
Realizing that DNMTs may be recruited to DNA by factors other than RelA/p65, we performed a re-ChIP assay using RelA/p65 as the first immunoprecipitation antibody. There is a TNF concentration-dependent increase in DNMT-1 recruitment to the BRMS1 promoter, but not on the cIAP2 promoter ( Figure 4d ). This analysis strongly suggests that DNMT-1 is part of the methylation complex recruited by RelA/p65 to chromatin. Importantly, this process appears to be gene specific and is likely dependent on the chromatin landscape of each promoter.
To ensure that our cell culture observations were relevant to human lung cancer, we performed ChIP analyses in patient specimens using the most common Figure 4 RelA/p65 is responsible for DNMT-1 assembling on BRMS1 promoter. (a) TNF increased the interaction of RelA/p65 and DNMT-1. NSCLC cells were treated with TNF (40 ng/ml) or not for 6 h. Co-immunoprecipitations (co-IPs) were performed using anti-DNMT-1 antibody, followed by immunoblotting for the presence of RelA/p65. (b) H157V/I cells were treated with 5-Aza as described above. ChIP analysis was performed at the indicated time points after removal of 5-Aza in H157 V/I cells by quantitative PCR specific to the BRMS1 promoter. Western blots show the expression of indicated proteins (nuclear RelA/p65, p50, DNMT-1 and a-tubulin) in H157 V/I cells. (c) H157 cells were transiently transfected with small interfering RNA (siRNA) control or p50. Post transfection (48 h), ChIP analysis was performed across the BRMS1 promoter, and the promoters of cIAP2 and GAPDH. The siRNA transfection efficiency was proved by western blot. (d) ChIP and re-ChIP analyses were performed in human embryonic kidney (HEK) 293T cells treated with TNF at the indicated doses for 16 h across the BRMS1 promoter, and the promoters of cIAP2 and GAPDH. Re-ChIP analysis used anti-RelA/p65 as the first immunoprecipitating antibody. (e) ChIP analyses were performed using samples of patients across the BRMS1 promoter, as well as the promoters of cIAP2 and GAPDH. Adeno, adenocarcinoma; N, matched adjacent noncancerous lung tissue; Squam, squamous cell cancer; T, lung tumor. lung cancer histologies-adenocarcinoma and squamous cell. Identical DNMT-1 and RelA/p65 assembly patterns were uniquely observed across the BRMS1 promoter, but not the cIAP2 or GAPDH promoters (Figure 4e ). Important differences in BRMS1 promoter occupancy are also demonstrated between adjacent noncancerous tissue and the tumor. Collectively, we have demonstrated that RelA/p65 is required for DNMT-1 and DNMT-3b binding to BRMS1 chromatin, which is responsible for the subsequent methylation and transcriptional repression of the BRMS1 promoter.
Inhibition of RelA/p65 DNA binding reduces chromatinassociated DNMT-1 and re-activates BRMS1 expression Crystallography has suggested that the region responsible for RelA/p65 binding to 3 0 subsite of kB binding sites occurs through Arg 33, Arg35, Tyr 36, Glu 39 and Arg 187 (Chen et al., 1998) . To better characterize the minimal interacting domain of RelA/p65 that binds to the BRMS1 promoter, we exploited the use of protein transduction domain (PTD) peptide that have been shown to be an effective way of delivering proteins in vitro and in vivo (Schwarze and Dowdy, 2000) . We synthesized and expressed three short RelA/p65 peptides including amino acids 31-40, 38-47 and 45-54, linked to an antennapedia PTD derived from the Drosophila homeotic transcription factor ANTP ( Figure 5a ). As shown in Figure 5b , the PTD-RelA/p65 (38-47) peptide blocked RelA/p65 DNA binding in a dosedependent manner.
In order to detect if these short PTD-RelA/p65 peptides could directly bind DNA, in vitro EMSAs were performed. As shown in Supplementary Figure S5A , only PTD-RelA/p65 (38-47) directly binds to kB binding site II. To confirm the specificity of our PTD-RelA/p65 (38-47) peptide, we mutated Glu 39 to Ala (E39A); the result is a complete abolishment of DNA binding of the PTD-RelA/p65 (38-47) peptide (Supplementary Figure S5A ). Data presented in Figure 5c and Supplementary Figure S5B highlight the dose-dependent effects of the PTD-RelA/p65 (38-47) on endogenous BRMS1 mRNA, methylation and protein levels compared with PTD controls. In stark contrast, examination of the known NF-kB-regulated genes, cIAP2, Bfl/A1 (Liu et al., 2006a) and IkBa, demonstrate a robust promoter. H157 cells were treated with 5-Aza as described previously. After removal of 5-Aza, cells were treated with indicated peptides (5 mg/ml) and TNF (20 ng/ml) for additional 24 h. ChIP analysis was performed.
RelA/p65 mediates promoter-specific methylation Y Liu et al decrease in these transcripts following PTD/p65 (38-47) exposure (Supplementary Figure S5C) . In aggregate, these data indicate that the PTD-RelA/p65 (38-47) peptide directly binds DNA and functions as a blocking peptide to compete with RelA/p65 binding. Moreover, as shown by others (Chen et al., 1998) , E39 is a critical amino acid for RelA/p65 DNA binding. Importantly, the above experiments provide solid evidence that RelA/ p65 binds to chromatin to transcriptionally activate some genes (cIAP2, Bfl/1A and IkBa), whereas in others (BRMS1) RelA/p65 clearly functions as an active transcriptional repressor.
To confirm that RelA/p65 (38-47) was the interacting domain required for RelA/p65 loading to chromatin, ChIP assays were performed. Following removal of 5-Aza, the pan-hypomethylated H157 lung cancer cells were pretreated with PTD-RelA/p65 (38-47) or PTD alone followed by stimulation with TNF (Figure 5d and Supplementary Figure S5D ). Glutathione S-transferase (GST)-PTD-RelA/p65 (38-47), but not GST-PTD, was found on the BRMS1 promoter, suggesting that it endogenously binds to the BRMS1 promoter and functions as a competitive inhibitor for kB binding sites on chromatin. In the presence of PTD-RelA/p65 (38-47), the recruitment of RelA/p65, methyl-histone H3-K9 and DNMTs were all dramatically decreased on the BRMS1 promoter.
These studies confirm that amino acids 38-47 are necessary for RelA/p65-mediated methylation and active repression of BRMS1. In addition, of the five important amino acids, only Glu 39 is located in this region, with mutation of Glu 39 completely abolishing the PTD-RelA/p65 (38-47) peptide DNA binding ( Figure 5 and Supplementary Figure S5 ).
The RelA/p65 109-120 region is required for DNMT-1 binding Next, we were interested in whether RelA/p65 binding to DNMT-1 was required for regulating promoter methylation and transcription of BRMS1. To experimentally address this, GST pull-down experiments indicated that the N-terminus region (1-245 amino acids) of RelA/p65 is responsible for the interaction with DNMT-1 (Figure 6a ). Using a series of N-terminal deletion constructs, we found that the first 108 residues in RelA/p65 do not affect RelA/p65-DNMT-1 interactions. However, expanding the deletion inclusive of 119 residues, RelA/p65 failed to bind DNMT-1 (Figure 6b ). We thus hypothesized that the RelA/p65 109-120 amino acid region was a strong candidate for the minimal interacting domain for RelA/p65 and DNMT-1.
To ascertain whether inhibition of the endogenous interaction between RelA/p65 and DNMT-1 had functional relevance, we synthesized and expressed a short PTD-linked RelA/p65 (109-120 amino acids) peptide. Following PTD-RelA/p65 (109-120) peptide treatment, the endogenous interaction of RelA/p65-DNMT-1 was significantly decreased in human embryonic kidney 293T and NSCLC cells (Figure 6c ). Interestingly, both BRMS1 mRNA and protein levels were increased after treatment with the PTD-RelA/p65 (109-120) peptide (Figure 6d and data not shown). To prove the specificity of RelA/p65 (109-120) peptide, a mutant of PTD-RelA/ p65 (109-120) peptide failed to affect the interaction of RelA/p65-DNMT-1 and BRMS1 mRNA (Supplementary Figure S6A and B) . This strongly suggests that DNMT-1 is involved in BRMS1 transcriptional regulation through interactions with RelA/p65.
To investigate if the PTD-RelA/p65 (109-120) peptide blocks the interaction of RelA/p65-DNMT-1 on chromatin resulting in decreased BRMS1 methylation, ChIP and re-ChIP assays were performed across the BRMS1 and cIAP2 promoters. Inhibition of RelA/p65 and DNMT-1 interaction dramatically reduces the recruitment of DNMT-1 to the BRMS1 promoter, without any effect on RelA/p65 promoter loading. In addition, using 5-methyl-cytidine as well-established mark of promoter methylation (Suzuki and Bird, 2008) , there is significant inhibition of basal BRMS1 promoter methylation. These results prove that RelA/p65 tethers DNMT-1 on chromatin to promote methylation and transcriptional repression of BRMS1 and that inhibition of RelA/ p65-DNMT-1 binding results in an increase in BRMS1 mRNA in NSCLC cells.
In addition, blocking RelA/p65--DNMT-1 binding using the PTD-RelA/p65 (109-120) peptide dramatically inhibited basal and TNF-stimulated invasion potential of lung cancer cells compared with the treatment with PTD only (Figure 6f ). These data confirm the biological function of RelA/p65-DNMT-1 binding in NSCLC cells.
Phosphorylation of serine 276 is required for RelA/ p65-DNMT-1 interactions on the BMRS1 promoter Recently, the Ghosh laboratory has demonstrated the importance of phosphorylation of serine 276 as a primary event that governs whether RelA/p65 functions as a transcriptional activator or as a basal transcriptional repressor (Zhong et al., 2002; Dong et al., 2008) . In our model system, we observed that S276A mutation in RelA/p65 resulted in a dramatic rescue of basal-and TNF-induced BRMS1 transcriptional repression. Neither K310R nor S536A mutants affected RelA/ p65-mediated BRMS1 transcriptional repression (Figure 7a ). These findings suggest that TNF-induced phosphorylation of S276 is important to RelA/ p65-mediated BRMS1 transcriptional repression. Importantly, the S276A mutant of RelA/p65 fails to bind DNMT-1 (Figure 7b) .
Finally, to investigate if phosphorylation of S276 is required for RelA/p65 and subsequent DNMT-1 loading to chromatin, ChIP and re-ChIP assays were performed as described above (Figure 7c ). The RelA/ p65 S276A mutant had no effect on the recruitment of RelA/p65 to BRMS1 and cIAP2 promoters compared with wild-type RelA/p65. Interestingly, the RelA/p65 S276A mutant dramatically inhibited DNA methylation (5-methyl-cytidine) on the BRMS1 promoter, compared with wild-type RelA/p65. Furthermore, re-ChIP assays indicated that the RelA/p65 S276A mutant cannot assemble DNMT-1 on the BRMS1 promoter. This strongly suggests that phosphorylation of serine 276 is required for DNMT-1 binding to RelA/p65 with subsequent loading of DNMT-1 to chromatin.
Discussion
In this report we show that TNF induction of the RelA/ p65 subunit of NF-kB is required for promoter methylation of BRMS1, a gene we have previously shown to be important in the metastatic movement of lung cancer cells (Smith et al., 2009) . RelA/p65 recruits DNMT-1 to chromatin, resulting in BRMS1 methylation. Moreover, we show that a specific post-translational event, S276 phosphorylation, is required for RelA/p65 binding to DNMT-1, the resulting recruitment of DNMT-1 to chromatin, specific CGI methylation and transcriptional repression (Figure 8) . These observations are supported by other studies demonstrating that transcription factors can induce DNA methylation through recruitment of DNMTs to the promoter, such as Stat3 (Zhang et al., 2005) , PML-RAR (Di Croce et al., 2002) and RelB (Puto and Reed, 2008) .
RelA/p65 activation is typically associated with promoting transcription (Baldwin, 1996; Wang et al., Figure 6 The region of RelA/p65 interacting with DNMT-1 is located in 109-119 amino acids. (a) The N-terminal of RelA/p65 is responsible for DNMT-1 binding. Human embryonic kidney (HEK) 293T cells were transfected with expression vector encoding myc-DNMT-1. GST pull downs were performed using GST-RelA/p65 fusion proteins and the presence of myc-DNMT-1 was analyzed by western blots. Coomassie blue indicates the relative amounts of GST fusion protein. (b) RelA/p65 (109-119) is critical for DNMT-1 binding. HEK 293T cells were transfected with indicated Flag-tagged RelA/p65. Immunoprecipitations (IPs) were performed using aFlag antibody, followed by immunoblotting for the presence of endogenous DNMT-1. (c) The PTD-p65 (109-120) peptide blocks RelA/p65 interacting with DNMT-1. HEK 293T and NSCLC cells were treated with the PTD peptides (5 mg/ml) for 24 h. IPs were performed using antibodies against DNMT-1 or IgG followed by immunoblotting for the presence of RelA/p65. (d) The PTD-p65 (109-120) peptide increases BRMS1 transcription. NSCLC cells were treated with the PTD peptides as described in (c). The mRNA of BRMS1 was analyzed by quantitative reverse transcription-PCR (RT-PCR). (e) ChIP and re-ChIP analyses were performed in NSCLC H157 cells treated with the PTD peptide as described in (c) across the BRMS1 promoter and cIAP2 promoter. Re-ChIP analysis used anti-RelA/p65 as the first immunoprecipitating antibody. (f) The PTD-p65 (109-120) peptide inhibits invasion of lung cancer cells. NSCLC cells were treated with the PTD peptides (5 mg/ml) and TNF (20 ng/ml) for 48 h. The invasion capability was quantified as described above. *Po0.01 compared with the treatment of PTD group; w Po0.01 compared with the No add group. 1996). However, depending on the stimuli, the specific gene and the unique chromatin landscape of that gene, transcription factors can have dual functions in transcriptional regulation. Examples of such dualfunctioning transcription factors include p53, Sp1, ERa, NF-Y and Stat3 (Hoffman et al., 2002; Zhang et al., 2005; Ceribelli et al., 2008; Mottet et al., 2009; Sankpal et al., 2009; Romano et al., 2010) .
NF-kB was first identified as an active transcriptional repressor by the Perkin's laboratory under cytotoxic stimuli such as ultraviolet light and doxorubicin (Campbell et al., 2004) . Following TNF treatment, RelA/p65 has also been reported to actively represses transcription of a 2(I) Collagen (Kouba et al., 1999) , hypoxia-inducible death factor BNIP3 (Shaw et al., 2006) and tumor suppressor PTEN (Kim et al., 2004; Xia et al., 2007) via directly binding the putative kB binding sites on chromatin.
Although reported mechanisms through which NF-kB is transcriptionally inactivated have largely been relegated to the ability of RelA/p65 to associate with histone deacetylases in unstimulated cells (Zhong et al., 2002; Dong et al., 2008) , it remains unclear how RelA/p65 functions as a transcriptional repressor in the presence of stimulation, such as TNF. Our studies identify a novel mechanism through which TNF induces RelA/p65 to function as an active repressor. This mechanism involves an inducible RelA/p65/ p50-mediated recruitment of DNMTs to chromatin that results in promoter methylation and transcriptional repression. Importantly, in our model system the ability of RelA/p65 to bind DNMT-1 is independent of histone deacetylase activities (Supplementary Figure S7) .
TNF activates RelA/p65 through inducing phosphorylation of S276 by protein kinase A (Zhong et al., 1997) or MSK1 (mitogen and stress-activated protein kinase-1) (Vermeulen et al., 2003) . Although previous reports suggest that RelA/p65 S276 phosphorylation results in preferential interaction with co-activator complexes for selected genes (Zhong et al., 2002; Dong et al., 2008) , we found that the S276 phosphorylation is required for RelA/p65 interacting with DNMT-1, DNMT-1 recruitment to the specific promoter and transcriptional repression. We postulate that phosphorylation of S276 may result in conformational changes of RelA/p65 that unmask CBP/p300 and DNMT-1 interacting domains. Whether CBP/p300 or DNMT-1 binds RelA/p65 is dependent on the gene-specific chromatin environment. In support of this theory, we observed that TNF temporally promotes RelA/p65 binding to the promoters of both the metastasis suppressor gene BRMS1 and the classic NF-kB-regulated gene cIAP2. However, in contrast to BRMS1, there is no CGI in the cIAP2 promoter and, thus, there is no chromatin loading of DNMTs. The result is a completely opposite effect on RelA/p65-mediated gene transcription: BRMS1 is transcriptionally repressed and cIAP2 is transcriptionally activated. It is probably because S276 Figure 7 RelA/p65 serine residue 276 is critical for RelA/p65-mediated BRMS1 transcriptional repression. (a) Mutation of RelA/p65 S276 failed to inhibit BRMS1 promoter activity. p65 À/À mouse embryo fibroblasts (MEFs) were transiently co-transfected with BRMS1-luc. reporter and expression vectors encoding indicated Flag-tagged RelA/p65. The luciferase activity was determined as described above. (b) RelA/p65 S276A cannot bind DNMT-1. p65 À/À MEFs were transfected with expression vector encoding indicated Flag-tagged RelA/p65. Co-immunoprecipitations (co-IPs) were performed as previously described. (c) Mutation of S276 significantly reduced RelA/p65-mediated DNMT-1 loading to the BRMS1 promoter. Human embryonic kidney (HEK) 293T cells were transfected with expression vector encoding indicated Flag-tagged RelA/p65. ChIP and re-ChIP analyses were performed across the BRMS1 promoter, and the promoters cIAP2 and GAPDH. Re-ChIP analysis used anti-Flag epitope as the first immunoprecipitating antibody.
Figure 8
RelA/p65 activates transcription through the dual mechanisms. In response to TNF stimulation, RelA/p65 directly activates transcription of classic NF-kB-regulated genes, such as cIAP2 and Bfl/A1. RelA/p65 can also function as an 'active repressor' to induce methylation and transcriptional repression of BRMS1, a known corepressor of RelA/p65, by assembly of DNMT-1 to chromatin. In this process, phosphorylation of serine 276 is required for the interaction of RelA/p65 with DNMT-1. Whether RelA/p65 functions as an inducible transcriptional activator or repressor depends on the chromatin landscape of the target genes. Moreover, the repression of BRMS1 transcription results in derepression of RelA/p65 transactivation through enhanced acetylation of K310, which further enhances RelA/ p65-mediated transcriptional activation.
RelA/p65 mediates promoter-specific methylation Y Liu et al phosphorylation results in differential RelA/p65 affinities to interact with co-activators or corepressors depending on the underlying chromatin landscape (Chen et al., 2000b) . Evidence of differential transcriptional activities following RelA/p65 phosphorylation has been noted by several groups. For instance, MSK1mediated RelA/p65 S276 phosphorylation transcriptionally activates IL-6, but not another NF-kB-regulated gene NFkB2 (Vermeulen et al., 2003) . RelA/p65 S276 phosphorylation by protein kinase A increases the transcription of NF-kB-regulated gene IL-4, but suppresses IL-2 (Neumann et al., 1995) .
An additional consideration as to whether RelA/p65 functions as a transcriptional activator or repressor is the location of the kB binding site relative to the CGI. As an example, there is differential regulation of GATA4 and SHP1, two Stat3 regulated genes, both with a CGI in their proximal promoters but with different locations of Stat3 binding regions (Zhang et al., 2005; Snyder et al., 2010) . We have previously demonstrated the functional significance of specific kB binding sites located within the promoter CGI region of BRMS1 (Nagji et al., 2010) confirming this additional layer of chromatin control over this process.
It is well established that RelA/p65 directly activates transcription of classic NF-kB-regulated genes (Wang et al., 1998; Chen et al., 2000a) . Our previous study indicated that BRMS1 functions as a corepressor to inhibit RelA/p65 transactivation potential by deacetylation of K310. In addition, small interfering RNA knockdown of BRMS1 significantly promotes both basal and TNF-induced RelA/p65-mediated transcription (Liu et al., 2006b) . In this study we demonstrate a previously undescribed mechanism through which RelA/p65 and BRMS1 mutually negatively coregulate each other's function in lung cancer cells. Following TNF exposure, RelA/p65 actively represses BRMS1 transcription through DNMT-1-mediated promoter methylation. Subsequently, this loss of BRMS1 results in derepression of RelA/p65 (via loss of the corepressor function of BRMS1; Liu et al., 2006b) , thus promoting the transactivation of RelA/p65 (Figure 8) .
In summary, we show that the TNF-induced phosphorylation of S276 of RelA/p65 results in recruitment of DNMT-1 to the BRMS1 promoter. This results in DNA methylation and active transcriptional repression of the metastasis suppressor BRMS1. It is likely that the ability of RelA/p65 to function as a transcriptional repressor is not unique to the BRMS1 promoter, but promoters with similar chromatin landscapes may also be regulated in a similar manner, making our observations broadly applicable. Our studies suggest that in addition to the known post-translational modifications of RelA/p65 that govern its function, promoter specifics such as CGI presence or absence, CGI location and the location of RelA/p65 binding regions on chromatin are also important determinants of whether RelA/p65 functions as an inducible transcriptional activator or repressor. Our data do suggest a novel mechanism through which NF-kB promotes cancer progression and may allow for the design and development of specific oncopharmacologic compounds that can selectively derepress important antimetastatic genes negatively regulated by RelA/p65 through targeting its DNA binding and/or DNMT-1 binding.
Materials and methods
Cells culture and surgical specimens Human NSCLC cell lines, normal bronchial epithelial cells, human embryonic kidney 293T cells and H157 I/V cells were maintained as previously described (Jones et al., 2000; Liu et al., 2006b) . Mouse embryo fibroblast cells were grown in Dulbecco's modied Eagle's medium with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). 5-Aza was purchased from Sigma Aldrich (St Louis, MO, USA). Human specimens were preserved as described previously (Liu et al., 2006b) .
Plasmid construction and antibodies
Human BRMS1-Luc promoter and the plasmid encoding Flag-tagged RelA/p65 were generated as described (Jones et al., 2000; Liu et al., 2006b) . The oligonucleotides encoding antennapedia PTD (DRQIKIWFQNRRMKWKK) or PTD-RelA/p65 peptides were inserted into pGEX-4T-1 (GE, Uppsala, Sweden) at BamHI/SalI sites. The BRMS1-luc kB-binding site mutants and mutant PTD-RelA/p65 peptides (E39A; 109-120 mutant: C109R/S112R/Q114H/N115K/ L116P) were generated using the quick-change mutagenesis kit (Stratagene, La Jolla, CA, USA). The following antibodies were used: RelA/p65, p50, DNMT-1, DNMT-3a, DNMT-3b, GST, IkB and RNA Pol II (Santa Cruz Biotech, Santa Cruz, CA, USA); Myc-tag, Acetyl-H3 and pan-methy-H3K9 (Cell signaling, Beverly, MA, USA); Flag-tag and a-tubulin (Sigma Aldrich); 5-methyl-cytidine (Eurogentec, San Diego, CA, USA). Small interfering RNA was purchased from Thermo Fisher Scientific (Lafayette, CO, USA).
Total RNA isolation and quantitative reverse transcription-PCR Total RNA was isolated and quantitative reverse transcription-PCR was performed as described previously (Liu et al., 2006b) .
Transfection and luciferase reporter assays Plasmids and reporter genes were transiently transfected and luciferase reporter activity assays were performed as described (Liu et al., 2006b) .
Methylation-specific PCR and bisulfite sequencing PCR
The genomic DNA was isolated using DNeasy blood and tissue kit (Qiagen, Valencia CA, USA), and quantitative methylation-specific PCR and bisulfite sequencing PCR were performed as described (Nagji et al., 2010) .
Electrophoretic mobility shift assay
The cells nuclear extracts (10 mg) were isolated and incubated with the P 33 -labeled BRMS1-kB binding sites as probes. In vitro EMSAs were performed using indicated GST-PTD peptides (2 mg) incubated with the P 33 -labeled BRMS1-kB binding sites as probes. The specificity of binding was examined by competition with the unlabeled oligonucleotides and antibodies against RelA/p65, Flag-epitope tag or GST.
Expression and purification of peptides GST-PTD-p65 peptides were expressed and purified as described (Liu et al., 2006b) . The GST fragments were cleaved from the peptides by incubating with thrombin (10 U/mg, Sigma, St Louis, MO, USA).
ChIP and re-ChIP assays ChIP and re-ChIP assays were performed as previously described (Hoberg et al., 2006; Liu et al., 2006b) .
Immunoprecipitation and western blot
Immunoprecipitation and western blot were performed as previously described (Liu et al., 2006b) .
Transwell migration and invasion assays
Migration and invasion of NSCLC cells were assessed as described (Smith et al., 2009) . Parallel experiments were performed in triplicate to assess migration in control chambers and invasion.
Statistical analysis
The results of all experiments represent the means±s.d. of three separate experiments performed in duplicate or triplicate.
Statistical differences were determined by a two-tailed, unpaired Student's t-test when appropriate. The P-values of o0.05 were considered significant.
